Piloting the Meanders of AIDS Research

Important note: Information in this article was accurate in 1996. The state of the art may have changed since the publication date.

Piloting the Meanders of AIDS Research

Journal of the International Association of Physicians in AIDS Care (12/96) Vol. 2, No. 12, P. 9
Mascolini, Mark

Abstract: At the 36th International Conference on Antimicrobial Agents and Chemotherapy, updates on trials of protease inhibitors were presented as well as data on even newer treatment options. Among the research topics covered were non- nucleoside reverse transcriptase inhibitors, a fusion inhibitor, and several new protease inhibitors. Researchers warned that clinicians should expect surprises as they treat patients with new, stronger antiretrovirals. As new research provides clinicians with a better understanding of HIV's pathogenesis, new drugs, and new ways to monitor drug efficacy, they should consequently be better prepared to treat the disease more strategically, noted Dr. Michael Saag of the University of Alabama at Birmingham. Clinical trials, however, only provide information on how a therapy works in a controlled situation. "Real-world" answers to questions about efficacy, resistance, and side effects must be discovered through clinical practice.

961230
AD962461

Copyright © 1996 - Information, Inc., Bethesda, MD. The CDC National Center for HIV, STD and TB Prevention provides the following information as a public service only. Providing synopses of key scientific articles and lay media reports on HIV/AIDS, other sexually transmitted diseases and tuberculosis does not constitute CDC endorsement. This daily update also includes information from CDC and other government agencies, such as background on Morbidity and Mortality Weekly Report (MMWR) articles, fact sheets, press releases and announcements. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC HIV/STD/TB Prevention News Update should be cited as the source of the information. Contact the sources of the articles abstracted below for full texts of the articles.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.

Always watch for outdated information. This article first appeared in 1996. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1996. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.